Your browser doesn't support javascript.
loading
The Role of a Cachexia Grading System in Patients with Non-Small Cell Lung Cancer Treated with Immunotherapy: Implications for Survival.
Turcott, Jenny G; Martinez-Samano, Julio E; Cardona, Andrés F; Bassarmal, Suraj Samtani; Ramírez-Tirado, Laura Alejandra; Zatarain-Barrón, Zyanya Lucia; Barrón, Feliciano; Corrales, Luis; Martín, Claudio; Barragán-Castillo, Pablo Alan; Ruiz-Patiño, Alejandro; Flores-Estrada, Diana; Arrieta, Oscar.
Afiliação
  • Turcott JG; Thoracic Oncology Unit, Instituto Nacional de Cancerología, Mexico City, Mexico.
  • Martinez-Samano JE; Oncology Unit, Médica Sur, Mexico City, Mexico.
  • Cardona AF; Clinical and Translational Oncology Group, Clínica del Country, Bogotá, Colombia.
  • Bassarmal SS; Oncology Unit, Foundation for Clinical and Applied Cancer Research - FICMAC, Bogotá, Colombia.
  • Ramírez-Tirado LA; Clinical Research and Biology Systems Department, Universidad el Bosque, Bogotá, Colombia.
  • Zatarain-Barrón ZL; Oncology Unit, Clinica Alemana, Santiago, Chile.
  • Barrón F; Thoracic Oncology Unit, Instituto Nacional de Cancerología, Mexico City, Mexico.
  • Corrales L; Thoracic Oncology Unit, Instituto Nacional de Cancerología, Mexico City, Mexico.
  • Martín C; Thoracic Oncology Unit, Instituto Nacional de Cancerología, Mexico City, Mexico.
  • Barragán-Castillo PA; Oncology Unit, Hospital San Juan de Dios, San José de Costa Rica, Costa Rica.
  • Ruiz-Patiño A; Medical Oncology Department, Thoracic Oncology Section, Instituto Fleming, Buenos Aires, Argentina.
  • Flores-Estrada D; Thoracic Oncology Unit, Instituto Nacional de Cancerología, Mexico City, Mexico.
  • Arrieta O; Oncology Unit, Foundation for Clinical and Applied Cancer Research - FICMAC, Bogotá, Colombia.
Nutr Cancer ; 73(5): 794-801, 2021.
Article em En | MEDLINE | ID: mdl-32482104
OBJECTIVE: The association between cancer-induced weight-loss (CIWL) and poor clinical outcomes in patients treated with immunotherapy is scarcely understood. We evaluated the use of a cachexia-grading system in IO-treated non-small cell lung cancer (NSCLC) patients in order to predict clinical outcomes. MATERIALS: 300 patients with NSCLC, who received immunotherapy during any line of therapy, were included. All patients were graded according to a previously validated cachexia scale, which takes into consideration body mass index (BMI) and weight loss, stratifying patients into five risk categories (0 [pre-cachexia] - 4 [refractory cachexia]). Primary endpoint was overall survival (OS). RESULTS: Ninety-one (30.3%) patients were classified in the low risk category, 176 (58.6%) were classified in the intermediate risk category and 33 (11%) were in the high risk category. Patients classified as low-risk had a significantly longer OS compared with those with intermediate or high risk (22.4 mo, [95%CI: 16.6-NR] vs. 17.1 [95%CI: 13.5-22.4] vs. 8.0 [3.9-18.4]; p < 0.001). In the multivariate analysis, after adjusting for age, hemoglobin and ORR, hazard of death increased as per the cachexia risk scale (Hazard ratio: 1.62 [1.22-2.16]; p = 0.001). CONCLUSION: Cachexia is independently associated with worse OS in NSCLC patients who receive immunotherapy, highlighting the role for nutritional assessment.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Humans Idioma: En Revista: Nutr Cancer Ano de publicação: 2021 Tipo de documento: Article País de afiliação: México País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Humans Idioma: En Revista: Nutr Cancer Ano de publicação: 2021 Tipo de documento: Article País de afiliação: México País de publicação: Estados Unidos